Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in Candida albicans
PLOS Biology · 2026
DOI: 10.1371/journal.pbio.3003631 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2026. Verfasst von Xin Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, United States of America. Hauptthemen laut MEDLINE: Candida albicans, Oxidative Stress, Drug Resistance, Fungal, Fungal Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Science Foundation.
Abstract (Originalsprache)
Drug resistance is a critical challenge in treating life-threatening fungal infections. Here, we uncover a mechanism of acquired azole resistance in Candida albicans through mutations in CAP1 , encoding a conserved fungal transcription factor that mediates the oxidative stress response. We analyzed 300 clinical isolates and identified 25 distinct CAP1 missense or nonsense mutations, with many occurring within the DNA-binding domain. We identified two nearly identical CAP1 heterozygous nonsense mutations, one in an isolate obtained from a bloodstream infection and one in a population of cells undergoing adaptation to fluconazole in vitro . Both CAP1 nonsense mutations resulted in loss of the C-terminal nuclear export signal, leading to nuclear retention of Cap1 and subsequent activation of genes associated with the oxidative stress response and drug transport. The CAP1 C-terminal truncations conferred significant fitness advantages in the presence of fluconazole, both in vitro and in a murine model of candidiasis. Strikingly, we discovered a therapeutic vulnerability: azole concentrations above the minimal inhibitory concentration were fungicidal to mutants with the CAP1 C-terminal truncation. The fungicidal effect was attributed to both elevated azole-induced reactive oxygen species and a compromised oxidative stress response in Cap1-truncated cells. Our results provide novel characterization of de novo CAP1 point mutations emerging in both laboratory and clinical contexts, elucidate the mechanisms underlying Cap1-regulated stress responses, and reveal a potential therapeutic target for overcoming drug resistance in C. albicans infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, United States of America.
- Division of Infectious Diseases, Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States of America.
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
ORCID-Profile: Xin Zhou, Anna Selmecki
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Science Foundation
- Burroughs Wellcome Fund
Zitieren
APA
Zhou, X., Hilk, A., Solis, N. V., Scott, N., Zajac, C., Filler, S. G., & Selmecki, A. (2026). Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in Candida albicans. PLOS Biology. https://doi.org/10.1371/journal.pbio.3003631
Vancouver
Zhou X, Hilk A, Solis NV, Scott N, Zajac C, Filler SG, et al. Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in Candida albicans. PLOS Biology. 2026. doi:10.1371/journal.pbio.3003631
BibTeX
@article{Zhou2026,
author = {Zhou, Xin and Hilk, Audrey and Solis, Norma V and Scott, Nancy and Zajac, Christopher and Filler, Scott G and Selmecki, Anna},
title = {Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in Candida albicans},
journal = {PLOS Biology},
year = {2026},
doi = {10.1371/journal.pbio.3003631}
}
EUVIMED